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background: Recent advances in our understanding of the causes of infertility and of assisted reproductive technology (ART) have led
to the development of complex diagnostic tools, prognostic models and treatment options. The Third Evian Annual Reproduction (EVAR)
Workshop Meeting was held on 26–27 April 2008 to evaluate evidence supporting current approaches to the diagnosis and management of
infertility and to identify areas for future research efforts.
methods: Specialist reproductive medicine clinicians and scientists delivered presentations based on published literature and ongoing
research on patient work-up, ovarian stimulation and embryo quality assessment during ART. This report is based on the expert presenta-
tions and subsequent group discussions and was supplemented with publications from literature searches and the authors’ knowledge.
results: It was agreed that single embryo transfer (SET) should be used with increasing frequency in cycles of ART. Continued improve-
ments in cryopreservation techniques, which improve pregnancy rates using supernumerary frozen embryos, are expected to augment the
global uptake of SET. Adaptation and personalization of fertility therapy may help to optimize efﬁcacy and safety outcomes for individual
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Advanced Access publication on April 20, 2009 doi:10.1093/humupd/dmp012patients. Prognostic modelling and personalized management strategies based on individual patient characteristics may prove to represent
real progress towards improved treatment. However, at present, there is limited good-quality evidence to support the use of these indivi-
dualized approaches.
conclusions: Greater quality control and standardization of clinical and laboratory evaluations are required to optimize ART practices
and improve individual patient outcomes. Well-designed, good-quality studies are required to drive improvements to the diagnosis and man-
agement of ART processes.
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Introduction
Infertility can be deﬁned as the failure to achieve a pregnancy
within 1 year of regular unprotected intercourse (Evers, 2002;
Zegers-Hochschild et al., 2006). Despite the inherent difﬁculties of
estimating the prevalence of infertility (Greenhall and Vessey, 1990),
it is generally accepted that one in four women are affected at
sometime (Gunnell and Ewings, 1994). Moreover, 20% of couples
consult their general physician because of difﬁculty conceiving, and
half of those couples (10%) require specialist care (Hull et al., 1985;
Beurskens et al., 1995).
Assisted reproductive technology (ART) treatment for infertile
couples now results in reasonably high pregnancy rates but may be
associated with risks of ovarian hyperstimulation syndrome (OHSS)
and multiple pregnancy (Van Voorhis, 2006). The variability in
patient characteristics and response to ART dictate the need for
proven, personalized diagnostic and therapeutic approaches to opti-
mize efﬁcacy and safety outcomes (Fauser et al., 2008).
Advances in our understanding of the causes of infertility and ART
have facilitated the development of increasingly complex diagnostic
tools, prognostic models and treatment options. It is hoped that the
identiﬁcation of reliable baseline demographic, disease or genetic charac-
teristics that are predictive of treatment outcome will enable selection of
the most appropriate management strategy for each couple. Further-
more, new laboratory techniques may facilitate the transfer of single
embryos while maintaining existing pregnancy rates (Van Voorhis, 2006).
Personalized management strategies, based on individual patient
characteristics, have been proposed and the further development of
these strategies may represent real progress towards individually tai-
lored fertility treatment. The Third Evian Annual Reproduction
(EVAR) Workshop Meeting was held on 26–27 April 2008 to evaluate
the existing evidence to support current approaches to the diagnosis
and management of infertility. Here, we report the discussions and
expert opinions of the EVAR Workshop Group based on presenta-
tions summarizing current literature and identify key areas for future
research efforts.
Methods
Prior to the Third EVAR Workshop Meeting in April 2008, specialist
reproductive medicine clinicians and scientists prepared presentations
based on published literature and ongoing research relating to patient
work-up, ovarian stimulation and embryo quality assessment during
ART. Following the presentations, group discussion to reach joint con-
clusions on the topics covered was facilitated by the chairmen: P.D.,
B.C.J.M.F. and K.D.
The content of this report is based on the expert presentations and
subsequent group discussions that took place during the workshop
meeting. Given the broad scope of this report, a systematic literature
review was not feasible. Instead, the discussions relating to each topic
were complemented with electronic literature searches via PubMed for
articles of any type that were published in the English language and unlim-
ited by date of publication. Combinations of the following keywords were
used to identify relevant articles: ‘assisted reproduction’, ‘ART’, ‘blasto-
cyst’, ‘cryopreservation’, ‘embryo’, ‘FSH’, ‘ICSI’, ‘individualized’, ‘infertility’,
‘IUI’, ‘IVF’, ‘LH’, ‘multiple pregnancy’, ‘outcome’, ‘ovarian’, ‘PGS’, ‘post-
coital test’, ‘prognostic’, ‘reserve’, ‘resistance’, ‘response’, ‘semen analy-
sis’, ‘SET’, ‘stimulation’, ‘tubal occlusion’ and ‘work-up’. The literature
search was also supplemented with key publications that were known to
the authors.
Individualized pretreatment
assessment
The accurate detection of underlying reproductive abnormalities helps
to guide individual management decisions and maximize ART treat-
ment outcomes. Clinical evaluation of the infertile couple may be
grouped into ﬁve categories: semen analysis, the post-coital test
(PCT), assessment of ovulation, uterine and tubal evaluation, and
laparoscopy (Balasch, 2000). Of these, semen analysis, mid-luteal
phase serum progesterone level and tubal patency evaluation com-
prise the initial basic patient work-up (Crosignani and Rubin, 2000).
However, the use of several fundamental elements of infertility
testing is still contentious, and evidence suggests that the current
World Health Organization (WHO) recommendations for the stan-
dard investigation of the infertile couple are poorly followed in
Europe (Rowe et al., 1993; Balasch, 2000).
Semen analysis
Humans have a low proportion of ‘normal’ sperm compared with
many other species. Although relatively few studies of semen analysis
have been performed in men with proven fertility, there is a high
degree of overlap in semen characteristics between fertile and infertile
men (Guzick et al., 2001). High-quality semen analysis has diagnostic
value for gross male infertility conditions (such as azoospermia or glo-
bozoospermia), but the predictive value of an individual semen analysis
is less robust when moderate numbers of motile sperm are present
(Comhaire, 2000).
Semen analysis comprises sperm concentration, motility and mor-
phology. No isolated semen analysis measures have been shown to
be diagnostic of infertility in large studies (Guzick et al., 2001). In an
effort to increase the value of semen analyses, results have been
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Hunault et al., 2004). However, the output of these models has
large conﬁdence intervals and results must be interpreted cautiously
(Snick et al., 1997; Hunault et al., 2004).
There are various methods for semen analysis, but those rec-
ommended by the WHO and the European Society for Human
Reproduction and Embryology (ESHRE) provide the most comprehen-
sive and robust methods (World Health Organization, 1999; Kvist and
Bjorndahl, 2002). Although a new manual is due to be published in
2009, the WHO currently deﬁnes ‘normal’ as a sperm concentration
of .20   10
6/ml with .50% of progressively motile sperm and the
presence of sperm with standard (no parameters provided) mor-
phology (World Health Organization, 1999).
Evidence suggests that the WHO recommendations for perform-
ance of semen analysis and reporting of results are adhered to
poorly in routine laboratory practice (Keel et al., 2002; Riddell et al.,
2005). Despite the availability of established systems to improve
staff training in semen assessments, such as ESHRE courses (Bjorndahl
et al., 2002), the majority of laboratories still do not have accurate
methods or appropriate training systems. Thus, semen analysis
results are often variable. The demonstrated absence of standardiz-
ation and strict quality control for semen analysis undermines the diag-
nostic and prognostic value of the test.
Despite the limitations described, semen analysis is routinely used
to evaluate the fertilization potential of the male partner in infertile
couples. Semen analysis outcomes also guide management decisions
and often inﬂuence the choice of expectant management, intrauterine
insemination (IUI), in vitro fertilization (IVF) or intracytoplasmic sperm
injection (ICSI).
Greater standardization of semen analysis and accurate laboratory
evaluation is clearly needed to improve the prognostic value of
semen analysis (Ombelet et al., 2003). Furthermore, high-quality
studies are required to identify threshold levels that are predictive of
treatment outcome to assist decision-making for ART treatment.
Sperm function tests may offer greater predictive power than tra-
ditional semen analysis but require strict validation prior to use in
routine clinical practice (Leﬁevre et al., 2007).
Post-coital test
The PCT provides an assessment of the quantity and quality of cervical
mucus, sperm–mucus interactions and the presence of antisperm
antibodies (Balasch, 2000; Glazener et al., 2000). The test involves
microscopic examination of extracted endocervical mucus, which
should be conducted in the pre-ovulatory phase and 8–12 h after
intercourse (Glazener et al., 2000). A positive PCT result may be
deﬁned as the presence of at least one forward-progressing spermato-
zoon in more than half of at least ﬁve high-power ( 400 magniﬁ-
cation) microscope ﬁelds (Glazener et al., 2000).
The PCT may provide an effective predictor of conception for
couples with an infertility history of ,3 years and no identiﬁed
female causes of infertility (Glazener et al., 2000). However, it has
been shown that the outcome of the PCT can be predicted for only
half of all infertile couples (in which the female partner has a regular
menstrual cycle) using the basic elements of an infertility history and
semen analysis results (van der Steeg et al., 2004). Furthermore,
results of the PCT are subject to considerable intra- and inter-
observer variability (Male Infertility Best Practice Policy Committee
of the American Urological Association and Practice Committee of
the American Society for Reproductive Medicine, 2006). Given the
widespread use of ART for couples with a negative PCT, routine
use of this test in clinical practice is not recommended (National Insti-
tute for Clinical Excellence, 2004; Male Infertility Best Practice Policy
Committee of the American Urological Association and Practice Com-
mittee of the American Society for Reproductive Medicine, 2006).
Uterine and tubal evaluation
Evaluation of the morphology of the uterus and fallopian tubes is
essential prior to initiating ART (Crosignani and Rubin, 2000).
Uterine and tubal structures may be visualized using a variety of tech-
niques, including hysteroscopy, hysterosalpingography (HSG), transva-
ginal ultrasonography (TVS), saline infusion sonohysterography (SIS),
magnetic resonance imaging (MRI) or laparoscopy.
Tubal occlusion is estimated to be the cause of infertility for 14% of
couples who require specialist treatment (Hull et al., 1985). The
optimum screening strategy to assess tubal damage is a complex
subject with currently no consensus of opinion (National Institute for
Clinical Excellence, 2004; den Hartog et al., 2008). A recent observa-
tional study comparing screening strategies for tubal factor infertility
with laparoscopy has provided valuable data (den Hartog et al.,
2008). Chlamydia trachomatis immunoglobulin G serology was shown
to discern accurately patients at high versus low risk of tubal pathology
and, thus, was suggested to provide a useful initial screening test (den
Hartog et al., 2008). HSG was worthwhile only for low-risk patients
to conﬁrm the absence of tubal pathology and confer potentially
beneﬁcial effects of tubal ﬂushing with oil-soluble contrast medium
(den Hartog et al., 2008). Laparoscopy with dye testing was considered
useful for patients with positive Chlamydia serology or evidence of
bilateral tubal occlusion on HSG (den Hartog et al., 2008).
The presence of hydrosalpinx has a negative effect on clinical preg-
nancyand live birth rates following IVF (Strandell, 2007). The mechanism
by which a hydrosalpinx impairs IVF success is incompletely understood,
but its removal prior to IVF is known to signiﬁcantly improve treatment
outcomes (Strandell, 2007). A Cochrane meta-analysis of data from
three clinical studies demonstrated superior pregnancy [odds ratio
(OR) 1.75, 95% conﬁdence interval (CI) 1.07–2.86] and live birth
rates (OR 2.13, 95% CI 1.24–3.65) following salpingectomy compared
with no surgical intervention (Johnson et al., 2004). Evidence from one
of these studies suggested that the beneﬁt of salpingectomy is greatest
for patients with ﬂuid-ﬁlled hydrosalpinges that are visible on ultrasound
examination (Strandell et al., 1999). Thus, patients with a hydrosalpinx
thatisvisibleonultrasoundshouldbeencouragedtoundergoprophylac-
tic salpingectomy prior to IVF.
The optimal management of endometriotic ovarian cysts in infertile
patients is less well deﬁned. Recent evidence of reduced responsive-
ness to gonadotrophins following laparoscopic ovarian cystectomy
has challenged the traditional surgical approach to treatment
(Somigliana et al., 2006). Indeed, it has been suggested that surgery
should be undertaken only for the treatment of large endometriomas
or pain that is refractory to medical treatment, or to exclude
malignancy (Garcia-Velasco and Somigliana, 2009).
Unexpected hysteroscopic abnormalities have been reported in up
to 40% of patients during ART work-up (Shamma et al., 1992; Doldi
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use of hysteroscopy before IVF or correction of identiﬁed pathology
leads to better treatment outcomes. Compared with hysteroscopy,
HSG has high sensitivity (81–98%) but low speciﬁcity (23–35%),
and high false-negative (10–90%) and false-positive (22–44%) rates.
Although hysteroscopy is considered the gold standard for identiﬁ-
cation of intrauterine pathology (Bozdag et al., 2008), recent advances
have enabled ultrasonographic techniques to increasingly substitute for
invasive screening procedures (Ekerhovd et al., 2004). Late follicular
phase TVS has proved to be a useful tool for the detection of intrau-
terine abnormalities such as polyps, synechiae, ﬁbroids and Mu ¨llerian
anomalies (Van Voorhis, 2008). SIS offers enhanced visualization of
the endometrium and better detection of intrauterine pathology
than does standard TVS, and may be as effective as hysteroscopy in
detecting intracavitary abnormalities (Ragni et al., 2005; Valenzano
et al., 2006). MRI may be used for patients with suspected complex
Mu ¨llerian anomalies (Deutch and Abuhamad, 2008).
Uterine ﬁbroids occur in 20–50% of women aged over 30 years and
are the most common benign tumour of the female genital tract
(Eldar-Geva et al., 1998; Okolo, 2008). These tumours are hetero-
geneous in composition, size, location and number (Pritts, 2001),
thus complicating the identiﬁcation of women who would beneﬁt
from myomectomy prior to ART treatment.
Retrospective data suggest that the presence of ﬁbroids ,4c mi n
diameter does not affect the outcome of ART treatment cycles
(Vimercati et al., 2007). Additional retrospective analyses suggest
that only ﬁbroids that encroach on the uterine cavity negatively
affect implantation rates and pregnancy outcomes in ART (Farhi
et al., 1995; Eldar-Geva et al., 1998). A meta-analysis suggested that
compared with infertile women without ﬁbroids, women with submu-
cosal ﬁbroids have signiﬁcantly lower rates of clinical pregnancy [rela-
tive risk (RR) 0.36, 95% CI 0.18–0.74], implantation (RR 0.28, 95% CI
0.12–0.65) and live birth (RR 0.32, 95% CI 0.12–0.85) (Pritts, 2001).
Removal of submucosal ﬁbroids improves clinical pregnancy rates (RR
2.03, 95% CI 1.08–3.83), but the limited available data suggest no
improvement in treatment outcomes after removal of intramural
ﬁbroids (Pritts, 2001).
Endometrial polyps have been identiﬁed by hysteroscopy in 16–
27% of women with otherwise unexplained infertility (Kim et al.,
2003; de Sa Rosa e de Silva et al., 2005). The beneﬁt of hysteroscopic
polypectomy on pregnancy rate has been demonstrated in a prospec-
tive, randomized study of women with ultrasonically diagnosed endo-
metrial polyps who were undergoing IUI (Perez-Medina et al., 2005),
in which patients who underwent polypectomy had a signiﬁcantly
higher cumulative pregnancy rate than those who underwent
hysteroscopy plus polyp biopsy (63.4% versus 28.2%, P , 0.001)
(Perez-Medina et al., 2005).
An association between polypectomy and improved spontaneous
pregnancy rates was also shown in ﬁve non-randomized studies
(Varasteh et al., 1999; Spiewankiewicz et al., 2003; Shokeir et al.,
2004; Stamatellos et al., 2008; Yanaihara et al., 2008). Retrospective
data suggest that hysteroscopic polypectomy improves pregnancy
rates in previously infertile women, regardless of the number or size
of polyps present (Stamatellos et al., 2008), and that resection of
polyps located at the utero-tubal junction may improve pregnancy
rates in infertile patients (Yanaihara et al., 2008). Although the effect
of endometrial polyps on IVF is unclear (Lass et al., 1999; Isikoglu
et al., 2006), data suggest that women with otherwise unexplained
infertility may still beneﬁt from polypectomy (Stamatellos et al., 2008).
In summary, prophylactic salpingectomy improves ART outcomes
for patients with a ﬂuid-ﬁlled hydrosalpinx. However, there are cur-
rently insufﬁcient high-quality data on the optimum screening modality
and management of other uterine and tubal abnormalities prior to
ART on which to base personalized patient care. Good-quality, pro-
spective studies are warranted to evaluate the relative merits of
uterine and tubal screening tests and management approaches prior
to ART treatment.
Evaluation of ovarian reserve
Ovarian stimulation is used in ART to stimulate multifollicular develop-
ment and enable multiple oocyte retrieval (Fauser et al., 2008). The
ovarian response to gonadotrophin stimulation depends primarily on
the woman’s ovarian reserve (Broekmans et al., 2006) and is a
major determinant of the success of IVF (van der Gaast et al., 2006;
Shanbhag et al., 2007).
Ovarian reserve represents the remaining population of primordial
and resting follicles (Gougeon, 1996) and is generally deﬁned as the
quantity and quality of the follicles present in the ovary (Broekmans
et al., 2006). For operational purposes, the ovarian reserve can be
deﬁned as the number of antral follicles present in the ovaries at a
given time that can be stimulated into dominant follicle growth by
exogenous follicle-stimulating hormone (FSH). Women with a
so-called ‘normal’ ovarian reserve will develop an average of 8–10
dominant follicles in response to conventional ovarian stimulation,
with a corresponding number of oocytes (Broekmans et al., 2006).
Although chronological age is the major determinant of ovarian
reserve, there is considerable individual variability in the rate of
ovarian ageing (Fig. 1) (te Velde and Pearson, 2002). Therefore, accu-
rate tests of ovarian reserve may allow individualized predictions of
oocyte yield and ART treatment outcome in terms of ongoing preg-
nancy (Broekmans et al., 2006).
Figure 1 Variation in reproductive ageing.
Adapted with permission from te Velde and Pearson (2002). Curve 1 shows
the Gaussian distribution of variation of age at menopause, Curve 2 the vari-
ation of age of transition from cycle regularity to irregularity, Curve 3 the
variation in age of becoming sterile and Curve 4 the variation in age of becom-
ing infertile.
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often used as tests of ovarian reserve (Broekmans et al., 2006). The
AFC correlates with the number of oocytes retrieved and ART out-
comes (Frattarelli et al., 2003) and is currently considered to be the
best available single predictor of ovarian response to stimulation
(Bancsi et al., 2002; Hendriks et al., 2007). Serum anti-Mu ¨llerian
hormone (AMH) levels may accurately identify patients at risk of an
extreme ovarian response (Nelson et al., 2007), but are infrequently
measured in routine practice (van Rooij et al., 2002; van Rooij et al.,
2005; Broer et al., 2009).
The evaluation of ovarian reserve may enable the identiﬁcation of
patients (with regular menstrual cycles) who will have a better or
worse response to gonadotrophin stimulation than would be expected
for their chronological age (Broekmans et al., 2006). In theory, this
would help clinicians to personalize patient management by selecting
an appropriate treatment protocol, stressing the need for early
initiation of treatment or counselling against initiation of treatment
(Broekmans et al., 2006).
Studies on the impact of ovarian reserve tests to select the appro-
priate starting dose of FSH have yielded contradictory results
(Popovic-Todorovic et al., 2003a, b; Klinkert et al., 2005; Olivennes
et al., 2009).
Although the potential use of AMH needs to be evaluated further,
all widely available tests of ovarian reserve are poor predictors of clini-
cal pregnancy and live births after IVF (Hendriks et al., 2005; Mol et al.,
2006). As such, a patient’s true ovarian reserve can be determined
only after a cycle of ovarian stimulation.
Management strategy selection
Expectant or active therapy
Infertilecouples can be divided into two groups:those whoare unable to
conceive without therapy and those who have reduced fertility but are
likely to conceive spontaneously with time (Crosignani and Rubin,
2000). Expectant management is the most appropriate approach for
infertile couples with a good prognosis for spontaneous pregnancy,
whereas ART provides a valuable treatment option for selected
couples with a low probability of natural conception (Hunault et al.,
2005). A reliable estimate of the likelihood of spontaneous pregnancy is
essential to enable clinicians to decide whether expectant or active man-
agement is more appropriate for a given couple (Hunault et al., 2004).
Prognostic models derive the likelihood of spontaneous pregnancy
in an individual couple based on large-sample data (Comhaire, 1987;
Eimers et al., 1994; Wichmann et al., 1994; Collins et al., 1995;
Snick et al., 1997). Statistical analysis of a model developed by Snick
et al. (1997) demonstrated that it would be predictive of a live birth
in 76–79% of infertile couples in a primary care setting. The most
important prognostic factors in this model were an abnormal PCT,
a tubal defect, an ovulatory defect and infertility of longer than
2 years (Snick et al., 1997). Although female age is considered to be
one of the most important factors to affect ART outcome (Templeton
et al., 1996; van Kooij et al., 1996), female age (,30 years) was pre-
dictive of live birth in this model only when the PCT result was
excluded (Snick et al., 1997).
The use of such prognostic models in clinical practice requires stan-
dardized screening assessments for all patients. Furthermore, there
are no strict criteria on which to base management decisions.
Hence, the likelihood of spontaneous pregnancy for each individual
couple must be weighed against the potential beneﬁts or risks of inter-
ventional treatment.
Active ART treatment options
IVF is an effective treatment option for female infertility, whereas ICSI
was developed for male infertility. Here, we discuss evidence to
support the use of these treatment options in cases of male infertility,
bilateral tubal occlusion and unexplained infertility.
Male infertility
Couples affected by severe male infertility related to conditions such
as obstructive or non-obstructive azoospermia require treatment
with ICSI to achieve pregnancy (National Institute for Clinical Excel-
lence, 2004). However, mild-to-moderate male infertility is a poorly
deﬁned concept and treatment strategies are highly variable.
Limited evidence suggests that IUI after clomiphene citrate stimu-
lation (CC-IUI) may be an effective ﬁrst-line therapy for male infertility
when the total inseminating motile sperm count after preparation is
.1   10
6/ml (Ombelet et al., 2003). Furthermore, CC-IUI still rep-
resents an effective therapeutic option when the inseminating motile
sperm count is ,1   10
6/ml if the sperm morphology score is at
least 4% (Van Waart et al., 2001; Ombelet et al., 2003). Despite
these ﬁndings, the authors of a recent Cochrane meta-analysis con-
cluded that there is insufﬁcient evidence to support the use of IUI
rather than timed intercourse (with or without ovarian stimulation)
for male infertility, and called for additional large, high-quality, random-
ized controlled trials to investigate this issue (Bensdorp et al., 2007).
There are also limited data to support the use of conventional IVF
or ICSI for mild-to-moderate male infertility. Clinical pregnancy rates
were similar after up to six cycles of IUI (with or without ovarian
stimulation) or IVF for male infertility in a prospective, randomized
study (Goverde et al., 2000). A meta-analysis of data from nine ran-
domized, controlled, sibling oocyte design trials of IVF versus ICSI
for couples with ‘borderline semen characteristics’ demonstrated a
pooled relative fertilization rate of 2.2 (95% CI 1.6–3.0) per oocyte
in favour of ICSI (Tournaye et al., 2002). However, fertilization rates
were not signiﬁcantly different in a sibling oocyte design study of
ICSI or high insemination concentration (0.8 sperm   10
6/ml) IVF
(67.6 versus 59.6; P ¼ 0.066) (Tournaye et al., 2002). There is a
need for high-quality trials comparing pregnancy or live birth rates
after IVF or ICSI for male infertility.
Given the lack of reliable evidence, the Third EVAR Workshop
Group advocated the use of a sibling oocyte technique (i.e. half of
the oocytes are inseminated by conventional IVF and half by ICSI) if
the likelihood of spontaneous fertilization is uncertain. However, the
group acknowledged that use of this technique depends on the retrie-
val of a sufﬁcient number of oocytes.
Bilateral tubal occlusion
The use of IVF and ICSI in a sibling oocyte design study of couples with
tubal infertility and normal semen showed similar mean fertilization rates
of 53% and 62%, respectively (Staessen et al., 1999). Moreover, no sig-
niﬁcant beneﬁt in clinical pregnancy or live birth rates was demonstrated
in an analysis of data from two pseudo-randomized controlled trials of
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(Aboulghar et al., 1996; Bukulmez et al., 2000).
Polycystic ovary syndrome
IVF is currently a third-line treatment option, after ovulation induction
and laparoscopic ovarian surgery, for women with anovulatory inferti-
lity due to polycystic ovary syndrome (PCOS), but it has been
suggested that older women may beneﬁt from earlier use of IVF
(Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop
Group, 2008). Analysis of baseline characteristics may enable identiﬁ-
cation of a subgroup of women who would beneﬁt from a tailored
treatment approach (Thessaloniki ESHRE/ASRM-Sponsored PCOS
Consensus Workshop Group, 2008). However, further work is
required to determine the optimal gonadotrophin stimulation protocol
for women with PCOS and the maternal age threshold for deviation
from the standard treatment algorithm.
Unexplained infertility
IUI is a commonly used treatment strategy for couples with unex-
plained infertility (Verhulst et al., 2006). Data have indicated a signiﬁ-
cantly higher live birth rate with IUI plus ovarian stimulation than with
IUI alone for unexplained infertility (OR 2.07, 95% CI 1.22–3.50)
(Verhulst et al., 2006).
The use of ovarian stimulation in combination with IUI is a contro-
versial and heavily debated topic (Fauser et al., 2005; Goverde et al.,
2005; van Rumste et al., 2006). Biologically, the use of ovarian stimu-
lation would be expected to increase the likelihood of a multiple preg-
nancy because the development of multiple dominant follicles and
ovulation of multiple oocytes is the aim of this intervention.
However, published literature contains conﬂicting reports, which
may be related to failure to induce multifollicular development or
cycle cancellation after the detection of three or more pre-ovulatory
follicles in half of the patients in some studies (Goverde et al., 2005;
Verhulst et al., 2006; van Rumste et al., 2006). Nonetheless, a
recent systematic literature review of studies of controlled ovarian
stimulation and IUI clearly demonstrated that multiple pregnancy
rates correlated positively with the number of pre-ovulatory follicles
(van Rumste et al., 2008).
Furthermore, the validity of pregnancy rates per cycle for compari-
sons of different treatment modalities could be questioned (Fauser
et al., 2005) when some interventions (e.g. timed intercourse or
natural cycle IUI) may be less costly or time-consuming and associated
with less patient discomfort and fewer complications. Regardless of
the treatment outcome evaluated, the workshop group believes that
singleton pregnancy should be the primary aim of ART treatment
and, as such, the beneﬁts of ovarian stimulation in combination with
IUI must be weighed carefully against the potential risks of a multiple
pregnancy.
No differences in live birth rates were demonstrated with IVF or IUI
either with (OR 1.15, 95% CI 0.55–2.4) or without (OR 1.96, 95% CI
0.88–4.4) ovarian stimulation in a Cochrane meta-analysis of clinical
trials of unexplained infertility (Pandian et al., 2005). ICSI is associated
with a signiﬁcantly lower rate of complete fertilization failure in cases
of unexplained infertility than conventional IVF (0.8% versus 19.2%;
P , 0.001) (Jaroudi et al., 2003). However, data from three random-
ized controlled trials indicate that clinical pregnancy rates are similar
following IVF or ICSI: 11% and 28%, respectively, per oocyte retrieval
(P ¼ 0.09) (Jaroudi et al., 2003); 32% and 38% (RR 0.83, 95% CI
0.48–1.45) (Bhattacharya et al., 2001); and 50% for both [not signiﬁ-
cant (P-value not provided)] (Foong et al., 2006).
In summary, evaluation of disease characteristics can help clinicians
to select the most appropriate active therapeutic option, thus allowing
basic tailoring of ART treatment to the individual. However, there is
little convincing evidence on which to base treatment strategies for
the majority of infertile couples (Table I). More high-quality data on
the relative superiority of each treatment option, and associated
adverse events, are needed to guide ART management decisions.
Comparison of well-deﬁned outcomes, such as (singleton or term)
live births per started treatment strategy rather than per treatment
cycle, should also be considered. Moreover, outcomes should be
viewed in the wider context of time taken to achieve pregnancy,
patient stress, likelihood of complications and overall costs of the
intervention and monitoring.
Individualized ovarian
stimulation
Ovarian stimulation protocols
The central paradigm of all ovarian stimulation protocols is to maxi-
mize the beneﬁcial effects of treatment (relating to high-quality
oocyte yield) while minimizing the potential risks associated with
........................................................................................
Table I Summary of available evidence on which to
base active ART management decisions
Indication IUI versus IVF Conventional IVF
versus ICSI
Mild-to-moderate
male infertility
No difference in
clinical pregnancy
rates (Crosignani
and Walters, 1994;
Goverde et al.,
2000)
ICSI increases fertilization
rates (RR 2.2, 95% CI
1.6–3.0) (Tournaye et al.,
2002)
Decreases fertilization
failure (Tournaye et al.,
2002)
There is no high-quality
evidence for an effect on
pregnancy rates
Tubal infertility Not applicable Leads to no difference in
clinical pregnancy rates
(Aboulghar et al., 1996;
Bukulmez et al., 2000)
Unexplained
infertility
No difference in live
birth rates (Pandian
et al., 2005)
Decreases fertilization
failure (Jaroudi et al.,
2003)
No difference in clinical
pregnancy rates
(Bhattacharya et al., 2001;
Jaroudi et al., 2003; Foong
et al., 2006)
ART, assisted reproductive technology; ICSI, intracytoplasmic sperm injection; IUI,
intrauterine insemination; IVF, in vitro fertilization.
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exogenous FSH required to induce follicle development is related to
the so-called FSH threshold and varies widely among women
(Brown, 1978; Schoemaker et al., 1993; Fauser and Van Heusden,
1997). Conventional daily doses of FSH in ART treatment protocols
range from 150 to 225 IU, but close monitoring and dose adjustment
is required because of the considerable inter-individual variability in
ovarian response (Fauser et al., 2008).
A requirement for elevated doses of FSH to induce multifollicular
development and increase the oocyte yield may indicate that a
patient is at the extreme of ovarian reserve (Tarlatzis et al., 2003).
Low mitochondrial DNA content has been reported to occur more
frequently in women with ovarian insufﬁciency than in those with
normal ovarian function (May-Panloup et al., 2005). The consequences
of impaired mitochondrial function in human oocytes are currently
unknown, but animal studies have shown that replacement of
ooplasm in ooplasmic-deﬁcient eggs will restore their developmental
capacity (Levron et al., 1996). The observed high rate of pregnancy
loss in women with reduced ovarian reserve (evidenced by elevated
basal FSH levels) indirectly supports the notion of a qualitative
reduction in oocyte quality (Levi et al., 2001).
The efﬁcacy and safety proﬁle of standard FSH stimulation protocols
vary according to individual patient characteristics. Four factors
(FSH, body mass index, female age and AFC) have been identiﬁed
to be predictive of ovarian response to FSH stimulation in women
aged ,35 years undergoing ART (Howles et al., 2006). These
factors have been combined into a model that predicts the
optimum starting dose of recombinant human (rh) FSH for individual
patients (Howles et al., 2006; Olivennes et al., 2009). Similar factors
were previously shown to predict the dose of exogenous FSH
required to induce ovulation in normogonadotrophic anovulatory
patients (Imani et al., 2002).
It is currently unclear from efﬁcacy, safety, tolerability or health
economic perspectives whether mild or maximal ovarian stimulation
(with cryopreservation of supernumerary embryos) is most beneﬁcial
(Fauser et al., 2005). Mild stimulation protocols [comprising a
gonadotrophin-releasing hormone (GnRH) antagonist for pituitary
suppression and low-dose FSH stimulation in the mid-to-late follicular
phase] may offer lower multiple pregnancy rates and lower costs than
standard ovarian stimulation, despite similar overall treatment efﬁcacy
(Heijnen et al., 2007). Accordingly, research efforts are ongoing to
optimize the efﬁcacy and safety proﬁles of stimulation protocols.
Evaluation of ovarian response to stimulation
There are no universally accepted deﬁnitions of normal, poor or
excessive responses to ovarian stimulation and the inconsistent deﬁ-
nitions used in different studies have hampered efforts to compare
treatment outcomes (Tarlatzis et al., 2003; Kailasam et al., 2004).
Many deﬁnitions relate to retrieved oocyte number, which is a
crude marker of response when used in isolation. Ovarian response
must be evaluated with reference to the stimulation protocol used,
including the daily and/or total dose of FSH administered and
co-treatment regimens (Kailasam et al., 2004; Verberg et al., 2009a).
Indeed, the retrieval of a small number of oocytes is the very aim of
mild stimulation protocols, although this would represent a poor
response following conventional ovarian stimulation (Verberg et al.,
2009b). Furthermore, it has been suggested that ovarian response
should be considered in the context of an individual’s expected
response to gonadotrophin stimulation (Klinkert et al., 2004).
Excessive ovarian response
The most serious iatrogenic complication of multifollicular ovarian
stimulation is severe OHSS, which is believed to be triggered by
human chorionic gonadotrophin (hCG) (Aboulghar and Mansour,
2003). This is a life-threatening condition, in which increased capillary
permeability results in haemoconcentration and hypovolaemia
(Papanikolaou et al., 2005).
There is some evidence that the incidence of early OHSS is limited
by the use of a GnRH antagonist (rather than a GnRH agonist)
for pituitary down-regulation (Al-Inany et al., 2006; Heijnen et al.,
2007), low-dose and mild FSH-stimulation protocols (Heijnen
et al., 2007), a GnRH agonist (Griesinger et al., 2007b; Engmann
et al., 2008) or low doses of hCG (Nargund et al., 2007) to trigger
ﬁnal oocyte maturation. Although coasting (withholding of gonado-
trophins) is often used to prevent OHSS (Mansour et al., 2005;
Nardo et al., 2006), a systematic review concluded that there is a
shortage of randomized controlled trials investigating such an
approach for the prevention of OHSS (D’Angelo and Amso, 2002).
The transfer of frozen–thawed embryos in natural cycles may be
used instead to limit the incidence of late OHSS (Mathur et al.,
2007). However, there are limited data to support the cryopreserva-
tion of all embryos (D’Angelo and Amso, 2007). Large randomized
trials are required to compare the risks and beneﬁts of different
ART treatment strategies for women at risk of OHSS (Aboulghar
and Mansour, 2003).
Poor ovarian response
Kailasam et al. (2004) attempted to deﬁne a poor ovarian response in
a retrospective study of IVF cycles in women aged under 40 years.
Based on this limited evidence and practical considerations, the work-
shop group proposed a deﬁnition of poor response to stimulation as
the retrieval of fewer than four oocytes (or cycle cancellation following
the development of fewer than three follicles) in response to an
ovarian stimulation protocol of 225 IU FSH per day (which represents
maximal ovarian stimulation) (Hoomans et al., 1999; Harrison et al.,
2001; Latin-American Puregon IVF Study Group, 2001; Out et al.,
2001; Yong et al., 2003; Out et al., 2004). Parameters of oocyte
maturity are not included in this deﬁnition.
Signs of diminished ovarian reserve may include age older than
40 years, the presence of fewer than ﬁve antral follicles of 2–5 mm
in diameter on TVS prior to treatment or an elevated basal FSH
level (Klinkert et al., 2004; Klinkert et al., 2005). A poor response
to gonadotrophin stimulation would be unexpected in patients who
have no signs of decreased ovarian reserve (Klinkert et al., 2004). A
retrospective cohort study showed higher cumulative pregnancy
rates (after a maximum of three cycles) among patients who had
experienced an unexpected versus expected poor response in their
ﬁrst IVF treatment cycle (37–47% versus 16–19%) (Klinkert et al.,
2004). Thus, patients who have an unexpected poor response to
stimulation still have a reasonable chance of pregnancy in subsequent
cycles (Klinkert et al., 2004; Hendriks et al., 2008).
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treatment regimen for patients with an expected or proven poor
response to ovarian stimulation (Shanbhag et al., 2007). Indeed, pro-
spective, randomized studies have shown little beneﬁt from daily doses
of rhFSH of  300 IU to induce follicular development (Tarlatzis et al.,
2003; Kailasam et al., 2004). Moreover, although evidence is conﬂict-
ing, high doses of FSH may stimulate the recruitment of immature or
chromosomally abnormal oocytes or have a detrimental effect on the
endometrium (Check et al., 1999; Katz-Jaffe et al., 2005; Kok et al.,
2006; Baart et al., 2007). In addition, chromosomal aneuploidy has
been observed in embryos from unstimulated IVF cycles in young
women (Verpoest et al., 2008).
Future elucidation of relevant genetic markers may allow the identi-
ﬁcation, prior to stimulation, of patients who are at risk of a poor
response or OHSS (Fauser et al., 2008).
Ovarian resistance to FSH
Early studies identiﬁed a subgroup of normogonadotrophic patients
who have normal estimated ovarian reserves but suboptimal
responses to FSH stimulation (De Placido et al., 2001, 2004, 2005;
Mochtar et al., 2007). Such women express ovarian resistance to
FSH but seem to be distinct from classical poor responders because
some investigators suggest that luteinizing hormone (LH) supplemen-
tation improves their ART treatment outcomes (Alviggi et al., 2006).
The incidence of ovarian resistance to FSH is poorly deﬁned in the
published literature, but it is believed to affect 10–15% of women
with normal ovarian reserve who undergo standard cycles of ART
(Alviggi et al., 2006). This subgroup can be identiﬁed by estradiol
levels of ,180 pg/ml or the absence of follicles of .10 mm in
diameter on Day 8 of a 150–300 IU FSH per day stimulation cycle
following GnRH agonist long-protocol pituitary down-regulation
(Alviggi et al., 2006).
It is believed that androgens, which are endogenously produced in
response to LH stimulation, are involved in sensitizing small antral fol-
licles to FSH (Durnerin et al., 2008). Profound suppression of
endogenous LH by GnRH agonists combined with the use of rhFSH
may cause LH activity to fall below a hypothetical threshold value in
some women. An observational trial by Alviggi et al. (2006) showed
that a common polymorphism of LH (v-LH) was present in a higher
proportion of patients who required .3500 IU compared with
,3500 IU FSH for follicular maturation (35% versus 2.6%). v-LH has
a short half-life and may be ineffective in supporting FSH-stimulated
multifollicular growth.
Despite these data, a meta-analysis showed no signiﬁcant difference
in live birth rates with or without LH supplementation of FSH stimu-
lation in a non-selected patient population (OR 0.92, 95% CI 0.65–
1.31); subgroup analyses also produced similar ﬁndings (Kolibianakis
et al., 2006). However, some of the studies reported above were
excluded from this meta-analysis because of co-treatment with vari-
able doses of FSH. Indeed, in a recent Cochrane systematic review,
a subanalysis of data from three clinical trials showed a signiﬁcantly
higher pooled estimate of ongoing pregnancy in poor responders
who had received co-treatment with rhLH than FSH alone (OR
1.85, 95% CI 1.10–3.11) (Mochtar et al., 2007). Additional data are
awaited, and pharmacogenomic studies may provide evidence of
associated biological pathways.
Embryo assessment
The use of embryo morphology scoring was prospectively evaluated
by Holte et al. The group assessed the ability of ﬁve real-time visual
embryo scoring variables to predict implantation of an individual
embryo after double-embryo, Day 2 transfer (Holte et al., 2007).
Cleavage stage, variation in blastomere size and the presence of
multinucleated cells were found to be independent markers of
embryo competence following the application of a conditional
multiple-regression model.
An increased understanding of the metabolic needs of embryos and
improvements in cell culture media have enabled prolonged in vitro
culture of embryos (Fig. 2) (Papanikolaou et al., 2008). Extension of
the in vitro culture period now allows the transfer of Day 5 blastocyst-
stage rather than early cleavage-stage embryos (Blake et al., 2007). A
recent meta-analysis showed signiﬁcantly higher rates of clinical
pregnancy (OR 1.27, 95% CI 1.03–1.55; P ¼ 0.02) and live births
(OR 1.39, 95% CI 1.10–1.76; P ¼ 0.005) following the transfer
of blastocyst-stage compared with cleavage-stage embryos
(Papanikolaou et al., 2008). Given the speed at which laboratory tech-
niques have evolved, it is essential to compare procedures and out-
comes to elucidate the best practices for maximal embryo viability.
The scientiﬁc rationale for blastocyst transfer is to increase implan-
tation rates by improving uterine and embryonic synchronicity and
allowing self-selection of embryos with greater implantation potential
(Wilson et al., 2002; Blake et al., 2007). However, there is little level I
evidence on which to base recommendations for morphology screen-
ing or blastocyst selection.
Greater standardization of blastocyst morphology scales is required
to allow comparison of study ﬁndings. In addition, validated, objective
measurements of blastocyst morphology and growth kinetics through-
out the culture period are required to increase the reproducibility of
results. Operator-independent computer-processing programmes
have shown promising ability to objectively assess blastocyst mor-
phology (Lemmen et al., 2008), but require further validation prior
to use in routine practice.
Selection of culture conditions
Individual laboratory culture strategies are complex and highly varied,
and there are few data on which to base the selection of a speciﬁc
culture strategy. For example, each culture ﬂuid contains up to 80
components that will inﬂuence embryo development and assessments.
Greater standardization of culture conditions is required to permit
accurate comparisons of embryo and/or blastocyst quality-assessment
tools.
Chromosomal evaluation
There is a high incidence of chromosomal abnormalities in human
embryos cultured in vitro (Munne, 2006) and the incidence of aneu-
ploidy increases with maternal age (Munne et al., 1995; Marquez
et al., 2000). Theoretically, identiﬁcation of chromosomal abnormal-
ities would permit selection of the healthiest embryos, and thus
increase live birth rates (Gianaroli et al., 1997; Wells and Delhanty,
2000). Unfortunately, embryo morphology correlates only partially
with its chromosomal status (Wells and Delhanty, 2000).
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be performed in up to 15 chromosomes using ﬂuorescence in situ
hybridization (Munne, 2006). PGS requires removal and analysis of a
single blastomere from a Day-3 embryo (Gianaroli et al., 1997; Wells
and Delhanty, 2000). Embryos with a normal genetic constitution are
subsequently selected for transfer and those with an abnormal
number of chromosomes are discarded (Mastenbroek et al., 2007).
The success of PGS depends on the assumption that the chromo-
somal constitution of a single blastomere is representative of the
entire embryo. However, mosaicism is now known to occur fre-
quently in early cleavage-stage embryos (Baart et al., 2006; Coulam
et al., 2007; Frumkin et al., 2008). The chromosomal constitution of
a preimplantation embryo may evolve during early cleavages, allowing
some mosaic embryos to develop normally (Baart et al., 2006;
Frumkin et al., 2008). Self-corrective mechanisms may include the
growth advantage of normal cells within a mosaic embryo (Bielanska
et al., 2002) or, in cases of trisomy, the active loss of the additional
chromosome (Munne et al., 2005; Frumkin et al., 2008).
Despite the promising results of early observational studies
(Gianaroli et al., 1999; Munne et al., 1999; Munne et al., 2003;
Montag et al., 2004), recent randomized controlled trials have
shown no improvement in pregnancy outcomes after PGS (Staessen
et al., 2004; Twisk et al., 2006; Mastenbroek et al., 2007; Hardarson
et al., 2008; Staessen et al., 2008; Fauser, 2008). Indeed, the use of
PGS may even reduce resulting pregnancy and live birth rates for
couples with advanced maternal age (Mastenbroek et al., 2007; Hard-
arson et al., 2008; Fauser, 2008).
In short, although evidence is conﬂicting (Goossens et al., 2008),
there is no good-quality evidence to support a beneﬁt of routine
PGS in the prediction of pregnancy outcomes (Staessen et al., 2004;
Baart et al., 2006; Twisk et al., 2006; Coulam et al., 2007). Thus,
current methods of PGS for aneuploidy have no place in current
ART treatment protocols (Twisk et al., 2006; Mastenbroek et al.,
2007; Fauser, 2008; Practice Committee of Society for Assisted
Reproductive Technology and Practice Committee of American
Society for Reproductive Medicine, 2008b).
Cryopreservation techniques
Cryopreservation of gametes, embryos and blastocysts is an essential
component of modern ART (Youssry et al., 2008). Successful cryopre-
servation maximizes cumulative pregnancy rates per oocyte retrieval
by storing unused embryos for future use (Youssry et al., 2008) and
allows delayed embryo transfer during a natural menstrual cycle (Lou-
tradi et al., 2008). Two cryopreservation techniques are available: the
conventional slow cooling method and the recently introduced rapid
procedure known as ‘vitriﬁcation’ (Youssry et al., 2008).
Vitriﬁcation results in signiﬁcantly improved survival of frozen–
thawed cleavage stage blastocysts and pregnancy rates, compared
with standard cryopreservation (Fig. 3) (Loutradi et al., 2008;
Youssry et al., 2008). However, there are concerns regarding the
high concentrations of potentially cytotoxic cryoprotectants used
during the vitriﬁcation process (Loutradi et al., 2008).
Chromosomal abnormalities have been reported in rapidly frozen
mouse embryos (Shaw et al., 1991). Thus, there is a potential risk
of serious malformations in human embryos following cryopreserva-
tion. Although no adverse effects of the transfer of cryopreserved
embryos on IVF outcomes, including malformations, were shown in
two European registry studies (Kallen et al., 2005; Pinborg et al.,
2008), more high-quality studies are required to assess long-term
Figure 2 Images of in vitro embryonic development showing morphology changes from culture Day 0 to Day 5.
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techniques (Shaw et al., 1991).
Frozen–thawed embryo or blastocyst
transfer schedule
Transfer of frozen–thawed embryos or blastocysts can be performed
during spontaneous ovulatory cycles, cycles of ovulation induction,
cycles in which the endometrium is artiﬁcially prepared using estrogen
and progesterone, and all with or without the use of a GnRH agonist
(Ghobara and Vandekerckhove, 2008). Despite these numerous
options, a recent Cochrane review found insufﬁcient evidence to
support the use of a particular transfer schedule (Ghobara and
Vandekerckhove, 2008).
Laboratory standards
and procedures
High laboratory standards and adherence to correct procedures are
critical to the outcome of ART. Unfortunately, there is currently
little good-quality evidence to support the use of speciﬁc ART-related
laboratory processes, including culture strategy and selection of blas-
tocysts for transfer. Furthermore, there is considerable variation in
quality and outcomes between IVF clinics and laboratories. This is
reﬂected in the considerable variation in cycle outcomes recorded
at individual UK clinics despite a country-wide policy of a maximum
of two embryos transferred (Human Fertilization and Embryology
Authority, 2008).
The observed inter-centre variability hampers agreement on, and
uptake of, best clinical and laboratory practices. In an attempt to stan-
dardize IVF laboratory techniques, the ESHRE has developed guide-
lines for good practice that require robust quality-management
programmes for each ART centre (Magli et al., 2008). Well-powered
studies to investigate ART-related laboratory practices and monitor
adherence to the recently published guidelines are warranted, and
we encourage professional bodies to promote such research efforts.
Single embryo transfer
Despite recommendations to limit the number of embryos transferred
(The ESHRE Capri Workshop Group, 2000; Land and Evers, 2003;
Wright et al., 2003; Practice Committee of Society for Assisted Repro-
ductive Technology and Practice Committee of American Society for
Reproductive Medicine, 2008a), at least 20–30% of IVF-related preg-
nancies are twin or higher-order multiple gestations (Reddy et al.,
2007; Andersen et al., 2008). Furthermore, approximately half of all
babies born from IVF globally are from multiple pregnancies
(Adamson et al., 2006).
Multiple pregnancy and birth is associated with a high incidence of
maternal and neonatal complications (Pandian et al., 2004; Wood,
2008) and, thus, considerable fetal morbidity and costs (ESHRE
Campus Course Report, 2001; Land and Evers, 2003). Indeed, when-
ever possible, elective single embryo transfer (eSET) is recommended
for young patients (aged ,35 years) (Practice Committee of Society
for Assisted Reproductive Technology and Practice Committee of
American Society for Reproductive Medicine, 2008a).
Randomized controlled trials have clearly shown that when only
fresh transfer cycles are evaluated, double embryo transfer (DET)
leads to higher pregnancy and live birth rates than eSET (Gerris
et al., 1999; Martikainen et al., 2001; Thurin et al., 2004; Lukassen
et al., 2005; van Montfoort et al., 2006). However, comparable
rates of cumulative clinical pregnancy (52.6% versus 47.9%; P ¼
0.24) and live births (42.9% versus 38.8%; P ¼ 0.30) have been
demonstrated following DET or eSET, respectively, when a single
frozen–thawed embryo transfer is also considered as part of the
same stimulation cycle (Thurin et al., 2004). Unsurprisingly, a recent
Cochrane meta-analysis demonstrated a signiﬁcantly lower multiple
pregnancy rate in women who underwent SET than DET (OR 9.97,
95% CI 2.61–38.19; P ¼ 0.0008) (Pandian et al., 2004). Health econ-
omic data also support the superior cost-efﬁcacy of SET over DET
when the number of deliveries with at least one live-born child and
all complications are considered (Kjellberg et al., 2006; Polinder
et al., 2008; Wood, 2008).
The group proposed that an acceptable rate of ART-related mul-
tiple pregnancies would be up to 10%. However, the worldwide
Figure 3 The odds of post-thawing survival rate of cleavage-stage embryos after vitriﬁcation or slow freezing.
CI, conﬁdence interval; OR, odds ratio. Total events: 1064 (vitriﬁcation), 937 (slow freezing). Test for heterogeneity: x
2 ¼ 15.94, df ¼ 2( P ¼ 0.001). Test for overall
effect: Z ¼ 3.73 (P ¼ 0.0002). Reprinted from Loutradi et al. (2008) with permission from Elsevier.
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(Reddy et al., 2007; Andersen et al., 2008). The observed resistance
to universal uptake of eSET in some societies is related to its perceived
low efﬁcacy; factors including advanced maternal age and few or poor-
quality oocytes retrieved are cited frequently to justify the transfer of
multiple embryos (ESHRE Campus Course Report, 2001;
van Montfoort et al., 2006; Practice Committee of Society for Assisted
Reproductive Technology and Practice Committee of American
Society for Reproductive Medicine, 2008a). This is confounded by
insufﬁcient awareness of the risks and costs associated with multiple
pregnancy among the general public and policy makers, the inability
to select the best-quality embryo, suboptimal cryopreservation pro-
cesses, constrictive cryopreservation legislation, the costs related to
repeated treatment cycles (particularly in low- and middle-income
countries) and competition between ART centres based on preg-
nancy/birth rates per cycle (Serour et al., 1991; ESHRE Campus
Course Report, 2001; Adashi et al., 2003; Fauser et al., 2005;
Karlstrom and Bergh, 2007).
Evaluation of ART treatment
outcomes
The single most relevant measure of success in ART is a controversial
and heavily debated topic (Land and Evers, 2003; Dickey et al., 2004;
Griesinger et al., 2004; Heijnen et al., 2004; Pinborg et al., 2004). Pre-
viously proposed criteria to evaluate successful ART treatment out-
comes include live birth rate per ovarian stimulation started
(Griesinger et al., 2004), healthy live birth rate per treatment cycle
(Dickey et al., 2004), singleton and multiple live birth rates per
started treatment cycle (Vayena et al., 2001) or term live birth per
started treatment strategy, which may include multiple cycles
(Heijnen et al., 2004). Because of the lack of a consistent deﬁnition
of ART success, national criteria for evaluation of treatment outcomes
tend to reﬂect the local economic and legal frameworks.
The Third EVAR Workshop Group concurred with the ESHRE rec-
ommendations and believes that the birth of a single healthy child
should be the aim of ART (Land and Evers, 2003). Therefore, the
group advocated the use of singleton delivery rates as the gold stan-
dard expression of ART treatment outcome. Nonetheless, cumulative
delivery rates per retrieved oocyte cohort using fresh and frozen
embryos, or per treatment strategy, must also be considered. The
group also believed that all comparisons of treatment modalities
must incorporate efﬁcacy and safety data, in addition to
health-economic evaluations.
The future of ART
As described, the Third EVAR Workshop Group believes that optim-
ization of singleton delivery rates should be the common aim of all
ART clinicians. Reproductive medicine specialists have a responsibility
to educate policymakers and the wider society on the risks of multiple
pregnancies and births. Furthermore, the group calls on national and
international professional bodies to issue guidelines promoting a
responsible attitude to eSET, and to help raise awareness of the
greater cost-efﬁcacy of SET compared with DET among healthcare
providers and policymakers.
Figure 4 New techniques for assessment of oocyte and embryo quality.
CGH, comparative genomic hybridization; FISH, ﬂuorescence in situ hybridization.
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are expected to have a huge impact on ovarian stimulation protocols
and increase the acceptance and uptake of SET around the world.
Improvements in cryopreservation outcomes may also encourage
the use of thawed embryos in subsequent natural cycles. This
process may help to avoid the consequences of gonadotrophin stimu-
lation on endometrium and late-onset OHSS.
New techniques in assessing oocyte and embryo quality could also
improve pregnancy and delivery rates per embryo transfer, thus
encouraging greater uptake of SET (Fig. 4). This may be achieved by
studying oocyte zona birefringence (Montag et al., 2008), gene
expression proﬁling of oocyte cumulus cells (McKenzie et al., 2004;
Assou et al., 2006; Feuerstein et al., 2007), evaluation of spent
culture ﬂuid by proteomic analysis (Katz-Jaffe et al., 2006) or metabolic
proﬁling using near-infrared spectroscopy (McKenzie et al., 2004;
Vergouw et al., 2008). Good-quality studies of these techniques will
help evaluate their potential clinical application and contribute to
our understanding of basic oocyte and embryo biology, and the
effects of iatrogenic ovarian stimulation.
The use of GnRH agonists to trigger ﬁnal oocyte maturation during
GnRH antagonist cycles is another promising approach to ART
(Griesinger et al., 2007a). Results of a small, observational,
proof-of-concept study suggest that GnRH agonist triggering (in combi-
nation with elective cryopreservation of two pronucleate oocytes) leads
to acceptable cumulative pregnancy rates while reducing the risk of
moderate-to-severe OHSS. Further investigation and validation of these
new ART treatment strategies in prospective studies are eagerly
awaited.Accurateidentiﬁcationof(genetic)markersofovarian response
to gonadotrophin stimulation would strengthen the development of pre-
dictive models of response and may enable the use of truly individualized
ART stimulation treatment protocols (Fauser et al., 2008).
Conclusions
In conclusion, members of the Third EVAR Workshop Group agreed
that SET should be the primary aim of many ART treatment cycles and
supported the use of singleton live birth rate as the reported outcome
measure from clinical trials and routine practice. However, the group
acknowledged that improved cryopreservation techniques are
required to further increase the global uptake of SET. Within this stan-
dard ART framework, adaptation and personalization of therapy may
help to optimize efﬁcacy and safety outcomes for individual patients.
Management decisions, including expectant therapy versus IUI, IVF
or ICSI, reﬂect a rudimentary individualization of therapy but are cur-
rently based on limited available evidence. Greater quality control and
standardization of clinical and laboratory evaluations are needed to
optimize ART practices and improve individual patient outcomes. Fur-
thermore, additional well-designed, good-quality studies are required
to drive improvements in the diagnosis and management of ART pro-
cesses in future years.
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